Bapineuzumab

drugbox
type = mab


source = Humanized
target =
CAS_number = 648895-38-9
ATC_prefix =
ATC_suffix =
ATC_supplemental =
PubChem =
DrugBank =
C=6466 | H=10018 | N=1734 | O=2026 | S=44
molecular_weight =
bioavailability =
protein_bound =
metabolism =
elimination_half-life =
excretion =
pregnancy_AU =
pregnancy_US =
pregnancy_category =
legal_AU =
legal_UK =
legal_US =
legal_status =
routes_of_administration =

Bapineuzumab is a humanized monoclonal antibody that acts on the nervous system and has potential therapeutic value for the treatment of Alzheimer's disease and possibly glaucoma. [cite journal
last = Sample
first = Ian
authorlink =
coauthors =
date = 2007-08-07
title = New Alzheimer's drugs might help prevent glaucoma
journal = The Guardian
url = http://www.guardian.co.uk/science/2007/aug/07/3
language = English
accessdate = 2008-06-18 ]

Bapineuzumab is an antibody to the beta-amyloid (Aβ) plaques that are believed to underlie Alzheimer's disease neuropathology. In previous clinical trials for the first iteration of the drug, called AN-1792, patients with Alzheimer's disease using active immunization had positive outcomes with removal of plaques and quality of life increases, but 6% of subjects developed aseptic meningitis and the trial was stopped. [cite journal
last = Woodhouse
first = Adele
authorlink =
coauthors = Dickson, Tracey C.; Vickers, James C.
year = 2007
title = Vaccination strategies for Alzheimer's disease: A new hope?
journal = Drugs & Aging
volume = 24
issue = 2
pages = 107–119
publisher = Adis International
location = Mairangi Bay, Auckland, New Zealand
issn = 1170-229X
pmid = 17313199
doi = 1170-229X/07/0002-0107/
language = English
url = http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=17313199
accessdate = 2008-06-18
quote = The vigour of international research on immunotherapy for AD provides significant hope for a strong therapeutic lead for the escalating number of individuals who will develop this otherwise incurable condition. ]

Bapineuzumab is currently being co-developed by the pharmaceutical companies Élan and Wyeth and entered Phase III trials in December 2007. [cite press release
title = Elan and Wyeth Announce Encouraging Top-line Results from Phase 2 Clinical Trial of Bapineuzumab for Alzheimer's Disease
publisher = Elan Corporation
date = 2008-06-17
format =
language = English
url = http://www.elan.com/news/full.asp?ID=1166655
accessdate = 2008-06-18
quote = Elan and Wyeth plan to continue all four studies in the previously disclosed bapineuzumab Phase 3 clinical program ]

References